Daily Biotech Pulse: Liver Disease-Focused Gene Therapy Pact, Assembly Bio Stops HBV Infection Trial, X4 Pharma Looks For Partners
Here's a roundup of top developments in the biotech space over the last 24 hours:
Goldman Sachs, Costco Get CNBC Fast Money Mentions, With This Stock Jumping 0.66% In Seconds
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors.
Here’s How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 15 Years
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 15 years by 9.04% on an annualized basis producing an average annual return of 15.59%. Currently, Vertex Pharmaceuticals has a market capitalization of $74.07 billion.
Cantor Fitzgerald Initiates Coverage On Vertex Pharmaceuticals with Overweight Rating, Announces Price Target of $365
Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight rating and announces Price Target of $365.
ViaCyte Acquisition Can Accelerate Vertex’s Ongoing Type 1 Diabetes Programs
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has agreed to acquire ViaCyte, a privately held biotechnology, for $320 million in cash. ViaCyte is focused…
Vertex Announces Letter Of Intent With The pan-Canadian Pharmaceutical Alliance For Public Reimbursement Of TRIKAFTA in Children With Cystic Fibrosis Ages 6 And Older
Vertex Pharmaceuticals Incorporated (Canada) (NASDAQ:VRTX) today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA), which represents an agreement in principle
This Biopharmaceutical Company Has A Better 1-Year Return Than Tesla, Apple, Starbucks, Nvidia And Microsoft
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) creates new possibilities via medicine to cure diseases and improve people's lives, and over the past year, marked gains in investors’ portfolios.
Why Jim Cramer Prefers Devon Energy Over EOG Resources
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Devon Energy Corporation (NYSE: DVN) over EOG Resources, Inc. (NYSE: EOG) as the former is cheaper.
$100 Invested In Vertex Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Vertex Pharmaceuticals (NASDAQ:VRTX) has outperformed the market over the past 20 years by 8.19% on an annualized basis producing an average annual return of 15.06%. Currently, Vertex Pharmaceuticals has a market capitalization of $67.67 billion.
Vectrus Shareholders Approve Combination with Vertex; Co. Will Be Renamed V2X, To Trade On NYSE Under Ticker VVX
Vectrus, Inc. (NYSE:VEC) today announced that based on voting results from the Special Meeting of Shareholders held today, Vectrus shareholders voted to approve the combination with Vertex. Following the close of the